Dose Modification

Dose modification with CYENDIV® (nintedanib) allows for the management of GI and liver side effects without compromising efficacy. For those patients who did not tolerate the 150mg dose, temporary dose reduction to 100mg twice daily was demonstrated to be beneficial.1

Cyendiv® efficacy and dose modifications1

Cyendiv® efficacy and dose modifications image
  • Cyendiv® may be resumed at the full dose (150mg twice daily) or reintroduced at a reduced dose (100mg twice daily), which subsequently may be increased to the full dose.1

Incidence of dose reduction and treatment interruption in INPULSIS® trials2

Incidence of dose reduction and treatment interruption in INPULSIS® trials image

Of those patients undergoing dose reductions:

  • 6% (40/178) of patients had ≥1 dose increase back to the full dose of CYENDIV® (150mg twice daily)2
  • 76% of patients in the CYENDIV® group received 150mg twice daily as their last dose at the end of the 52-week trial2

Watch Professors Cottin and Richeldi discuss Cyendiv® dose modifications

References

  1. Richeldi L., et al. Effect of dose reductions, treatment interruptions and dose intensity on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS® trials (Poster). PFF Summit 2015;Washington DC, US.
  2. Corte T., et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015;16. Available at:
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581488/. Accessed January 11, 2016.